

Franco Granella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11884656/publications.pdf>

Version: 2024-02-01

81
papers

4,073
citations

136950

32
h-index

123424

61
g-index

83
all docs

83
docs citations

83
times ranked

3660
citing authors

#	ARTICLE	IF	CITATIONS
1	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2022, 269, 933-944.	3.6	10
2	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2022, 28, 472-479.	3.0	13
3	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1034-1040.	3.0	37
4	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 535-542.	3.3	8
5	Risk of Getting COVID-19 in People With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	31
6	Comparing natural history of early and late onset pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2022, , .	5.3	6
7	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. <i>Brain</i> , 2022, 145, 2796-2805.	7.6	38
8	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210845.	3.0	2
9	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Pharmacoeconomics</i> , 2022, 40, 323-339.	3.3	3
10	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.1	12
11	Herpes zoster preceding neuromyelitis optica spectrum disorder: casual or causal relationship? A systematic literature review. <i>Journal of NeuroVirology</i> , 2022, 28, 201-207.	2.1	2
12	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, , .	3.3	1
13	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	3.0	11
14	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. <i>Multiple Sclerosis Journal</i> , 2021, 27, 695-705.	3.0	7
15	Detection of disability worsening in relapsing–remitting multiple sclerosis patients: a real–world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. <i>European Journal of Neurology</i> , 2021, 28, 567-578.	3.3	6
16	Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy. <i>Neuroepidemiology</i> , 2021, 55, 224-231.	2.3	4
17	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	3.5	48
18	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	3.0	3

#	ARTICLE	IF	CITATIONS
19	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	5.3	370
20	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.1	41
21	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 726.	9.0	26
22	Secondary cluster headache due to a contralateral demyelinating periaqueductal gray matter lesion. <i>Headache</i> , 2021, 61, 1136-1139.	3.9	2
23	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	3.7	86
24	The effectiveness of natalizumab vs fingolimod- A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	2.0	8
25	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 208, 106180.	4.7	21
26	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	5.9	8
27	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021, 430, 118067.	0.6	9
28	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.1	54
29	Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1519-1531.	3.0	38
30	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	3.0	52
31	Migraine Awareness in Italy and the Myth of "Cervical Arthrosis" Headache, 2020, 60, 81-89.	3.9	13
32	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	2.0	29
33	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1297-1303.	1.9	27
34	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	7.6	24
35	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , 2020, 143, 3013-3024.	7.6	53
36	Neuromyelitis Optica Spectrum Disorder Attack Triggered by Herpes Zoster Infection. <i>Multiple Sclerosis International</i> , 2020, 2020, 1-3.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	7.6	32
38	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. <i>Journal of Neurology</i> , 2020, 267, 3008-3020.	3.6	19
39	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 307-316.	10.2	219
40	Location of first attack predicts the site of subsequent relapses in multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2020, 74, 175-179.	1.5	2
41	Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month) Tj ETQq1 1 0.784314 rgBT /Overlook 414, 116827.	0.6	9
42	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101430.	2.0	23
43	Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey. <i>Journal of Neurology</i> , 2019, 266, 3031-3037.	3.6	17
44	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. <i>Frontiers in Neurology</i> , 2019, 10, 916.	2.4	21
45	The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 146-152.	2.0	13
46	Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 32, 27-29.	2.0	18
47	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	1.9	71
48	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	2.0	35
49	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	7.4	336
50	Health-related quality of life in clinically isolated syndrome and risk of conversion to multiple sclerosis. <i>Neurological Sciences</i> , 2019, 40, 75-80.	1.9	10
51	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 166.	2.0	0
52	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 105-108.	2.0	22
53	First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence. <i>Current Medical Research and Opinion</i> , 2018, 34, 1803-1807.	1.9	13
54	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	3.0	37

#	ARTICLE	IF	CITATIONS
55	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , 2018, 265, 2851-2860.	3.6	43
56	Silent lesions on MRI imaging “ Shifting goal posts for treatment decisions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1569-1577.	3.0	8
57	Inhaled migraine drug therapy: a start of the art therapeutic strategy or just another gimmick?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1743-1745.	1.8	2
58	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407.	9.0	20
59	Correlation between cortical lesions and cognitive impairment in multiple sclerosis. <i>Brain and Behavior</i> , 2018, 8, e00955.	2.2	23
60	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	3.0	30
61	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	1.9	49
62	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	10.2	134
63	Definitive childlessness in women with multiple sclerosis: a multicenter study. <i>Neurological Sciences</i> , 2017, 38, 1453-1459.	1.9	35
64	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059.	1.1	38
65	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	7.6	94
66	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	7.6	281
67	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	1.9	63
68	Comparative efficacy of first-line natalizumab vs IFN- β or glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 102-115.	1.6	33
69	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	5.3	158
70	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405.	9.0	100
71	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , 2015, 138, 3275-3286.	7.6	76
72	Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study. <i>Current Medical Research and Opinion</i> , 2014, 30, 1849-1855.	1.9	17

#	ARTICLE	IF	CITATIONS
73	Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study. <i>Journal of Neurology</i> , 2013, 260, 1583-1593.	3.6	29
74	Italian guidelines for primary headaches: 2012 revised version. <i>Journal of Headache and Pain</i> , 2012, 13, 31-70.	6.0	129
75	Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium. <i>Journal of Headache and Pain</i> , 2008, 9, 367-373.	6.0	35
76	Multicenter Case-Control Study on Restless Legs Syndrome in Multiple Sclerosis: the REMS Study. <i>Sleep</i> , 2008, 31, 944-952.	1.1	175
77	Hemicrania horologica (â€œclock-like hemicraniaâ€). <i>Neurology</i> , 2003, 60, 1722-1723.	1.1	4
78	Course of primary headaches during hormone replacement therapy. <i>Maturitas</i> , 2001, 38, 157-163.	2.4	93
79	Nocturnal Eating Syndrome in Adults. <i>Sleep</i> , 1994, 17, 339-344.	1.1	108
80	Migraine Without Aura and Reproductive Life Events: A Clinical Epidemiological Study in 1300 Women. <i>Headache</i> , 1993, 33, 385-389.	3.9	257
81	A New 5-HT ₂ Antagonist (Ritanserin) in the Treatment of Chronic Headache With Depression. A Double-Blind Study vs Amitriptyline. <i>Headache</i> , 1990, 30, 439-444.	3.9	34